Table 1 Patient characteristics, toxicities, and response to therapy
Patient code | Age | Sex | Stage | Disease sites | Prior therapy | Tremelimumab doses, no. | Treatment-related toxicity, G2/G3 | Best response |
|---|---|---|---|---|---|---|---|---|
1103 | 80 | M | IVc | Liver | 2 | Diarrhea G2 | PD | |
Lung | ||||||||
1104 | 63 | M | IVb | LN | Temozolomide, thalidomide, IL-2 | 2 | PD | |
Lung | ||||||||
Liver | ||||||||
Adrenal | ||||||||
Kidney | ||||||||
1105A | 61 | M | IVc | LN | Cisplatin, vinblastine, temozolomide, IL-2, IFN, lenalidomide, MART1/DC | 11 | Hepatitis G3 Acne Rosacea G2 | SD × 11 mos |
Lung | ||||||||
Stomach | ||||||||
1105P | 55 | F | IVc | LN | Cisplatin, vinblastine, dacarbazine, paclitaxel, gefitinib, BCG, IL-2, IFN | 4 | PD | |
Lung | ||||||||
Liver | ||||||||
1106 | 52 | F | IVc | LN | Cisplatin, vinblastine, dacarbazine | 4 | Diarrhea G3 Rash G2 | PD |
Lung | ||||||||
Liver | ||||||||
1107 | 57 | M | IVc | LN | Heat shock | 2 | PD | |
Liver | Protein | |||||||
1108 | 55 | F | IIIc | SC | GM-CSF | 5 | Hepatitis G3 Hypophysitis G2 | CR × 39+ mo. |
LN | ||||||||
1109 | 54 | M | IVa | LN | ILX 651 | 3 | Leuko-cytoclastic vasculitis G3 | PD |
1110 | 34 | M | IVa | SC | IL-2 | 3 | PD | |
LN | ||||||||
1111 | 90 | M | IIIc | Skin | BCG, | 8 | Diarrhea G2 | PR × 34+ mo. |
LN | AMG 706 | |||||||
1113 | 63 | M | IVa | LN | IFN | 22 | Hypophysitis G2 Elevated trans-aminases G2 Asthenia G2 Arthralgia G2 Grover's G2 Uveitis G2 | pPR × 33+ mo. |
1114 | 61 | M | IVa | LN | IFN, temozolomide | 2 | Colitis G3 | SD × 8 mo. |